| http://purl.uniprot.org/citations/14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/14978253 | http://www.w3.org/2000/01/rdf-schema#comment | "Clinically, there is a great need for small molecule inhibitors that could control pathogenic effects of transforming growth factor (TGF-beta) and/or modulate effects of TGF-beta in normal responses. Inhibition of TGF-beta signaling would be predicted to enhance re-epithelialization of cutaneous wounds and reduce scarring fibrosis. Selective small molecule inhibitors of the TGF-beta signaling pathway developed for therapeutics will also be powerful tools in experimentally dissecting this complex pathway, especially its cross-talk with other signaling pathways. In this study, we characterized 2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine hydrochloride (SB-505124), a member of a new class of small molecule inhibitors related to imidazole inhibitors of p38, which inhibit the TGF-beta type I receptor serine/threonine kinase known as activin receptor-like kinase (ALK) 5. We demonstrate that this compound selectively and concentration-dependently inhibits ALK4-, ALK5-, and ALK 7-dependent activation of downstream cytoplasmic signal transducers, Smad2 and Smad3, and of TGF-beta-induced mitogen-activated protein kinase pathway components but does not alter ALK1, ALK2, ALK3 or ALK6-induced Smad signaling. SB-505124 also blocks more complex endpoints of TGF-beta action, as evidenced by its ability to abrogate cell death caused by TGF-beta1 treatment. SB-505124 is three to five times more potent than a related ALK5 inhibitor described previously, SB-431542."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.org/dc/terms/identifier | "doi:10.1124/mol.65.3.744"xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/author | "Roberts A.B."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/author | "Laping N.J."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/author | "Major C."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/author | "DaCosta Byfield S."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/date | "2004"xsd:gYear |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/name | "Mol Pharmacol"xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/pages | "744-752"xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/title | "SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7."xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://purl.uniprot.org/core/volume | "65"xsd:string |
| http://purl.uniprot.org/citations/14978253 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/14978253 |
| http://purl.uniprot.org/citations/14978253 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/14978253 |
| http://purl.uniprot.org/uniprot/#_P0CG37-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P51864-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P13385-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_Q13705-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P27539-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_Q15796-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P27037-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P84022-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_P36896-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_Q96S42-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |
| http://purl.uniprot.org/uniprot/#_Q8NER5-mappedCitation-14978253 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/14978253 |